The launch of Selincro® - the first and only medicine approved for the reduction of alcohol consumption in alcohol-dependent patients - will commence in
Denmarktoday. Valby, 2013-09-30 07:00 CEST(GLOBE NEWSWIRE) -- H. Lundbeck A/S(Lundbeck) today commenced its launch of Selincro® in Denmark, making the product available to alcohol-dependent patients in Denmarkwith a high drinking risk level. It is estimated that 585,000 Danes have a harmful alcohol intake, of whom about 140,000 are alcohol-dependent1. The socio-economic costs associated with alcohol abuse in Denmarkamount to approximately DKK 10 billioneach year2. Of this amount, expenses for medical treatment of alcohol consumption amount to only DKK 10.8 million, or close to 0.1% of the total costs. Antabus®, which has been on the market since19553, currently account for 95.5% of all pharmaceutical treatments. ”The fact that a very large group of alcohol-dependent patients receive no treatment involves huge human and economic costs. We have been looking forward to making Selincro® available to Danish patients, and we are proud to launch a new treatment regime that offers new possibilities for the treatment of alcohol-dependent patients,” said Ole Chrintz, Senior Vice President, International Markets and Europeat Lundbeck. Selincro® is the first and only medicine approved for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. In clinical trials, Selincro® in conjunction with psychosocial intervention has reduced alcohol consumption by 61% after six months of treatment5, and for the recruited patients this corresponded to an average reduction equal to nearly one bottle of wine per day. Earlier this year, Selincro® was launched in Norway, Finland, Poland, Estonia, Latvia, Lithuania, Portugal, Iceland, Sweden, the UK, Bulgaria, the Czech Republic, Hungary, Slovenia and Italy. On 24 September 2013, Selincro® won the Confederation of Danish Industry's2013 product award. About Selincro® Selincro is a so-called opioid-receptor modulator. The compound acts by affecting the mechanism in the brain that may cause a continuing and uncontrolled intake of alcohol. This means that Selincro may be prescribed in conjunction with psychosocial intervention to help control and limit the alcohol intake.